NashBio Unveils Innovative Data Solutions to Enhance Efficiency in Life Science Research and Development

Nashville Biosciences LLC (NashBio), a prominent player in the realm of real-world, multi-omics data, has today unveiled the introduction of several next-generation real-world data (RWD) solutions. This initiative includes a research platform and therapeutic area collections that will roll out over the next six months. These innovations promise to provide unparalleled access to deidentified electronic health records (EHR) and associated genomic data, enabling life science researchers, pharmaceutical firms, and biotech pioneers to derive actionable insights, expedite therapeutic breakthroughs, enhance equitable healthcare outcomes, and address significant data voids in precision medicine.

The available options consist of:

• Therapeutic-Area Data Collections: Expertly curated, specialty aligned datasets designed to make complex clinical data features in high priority focused therapeutic areas, such as cardiology and hepatology, easy to use and transform the way clinical phenotypes are developed, and endpoints are analyzed (available now)
• Secure Research Platform: A scalable, cloud-based, data-as-a-service (DaaS) subscription platform that empowers researchers to rapidly identify and analyze patient cohorts using disease-specific phenotypes, longitudinal clinical data, and genomic insights on their own terms and timelines (available spring 2025)

“NashBio's advanced data solutions mark a significant advancement in the field of precision medicine research,” stated Leeland Ekstrom, PhD, the CEO of NashBio. “We aim to simplify intricate healthcare data for researchers and innovators. Through the integration of these services, we empower our clients with the necessary resources to accelerate discoveries with enhanced accuracy.”

For a long time, obtaining comprehensive, cohesive, and high-quality clinical and genomic data from the real world has posed significant challenges for effective life sciences research. NashBio addresses these obstacles by facilitating easier access to data and streamlining analysis, allowing researchers to expedite their learning process. This approach not only helps in hastening therapeutic development but also shortens discovery timelines, paving the way for significant advancements in the field.

These products will serve as essential instruments for uncovering disease mechanisms, confirming biomarkers, and speeding up the discovery of therapeutic targets. By integrating high-quality electronic health records (EHR) with genomic information tailored to particular treatment requirements, researchers can identify the most relevant datasets for their investigations, facilitating the quicker development of novel drugs and diagnostic tools. Healthcare institutions and providers will experience enhanced insights into diseases, more effective treatments based on evidence, and opportunities for earlier interventions. Patients will benefit from fair access to superior, more precisely targeted therapies driven by a broad range of genomic data and expedited progress in precision medicine.

“These offerings are based in part on what we learned from how the Alliance for Genomic Discovery's (AGD) members use RWD, and